Items tagged with Drug-resistant TB
Oral six-month treatment for MDR-TB is safe and effective in people with HIV (post)
An all-oral treatment regimen for multidrug-resistant tuberculosis (MDR-TB) recently recommended as a new standard of care by the World Health Organization is effective and safe in people living with HIV, Dr Ilaria Motta of Médecins sans Frontières reported at the 24th International AIDS Conference (AIDS 2022) in Montreal.
RESIST-TB July 2022 newsletter (post)
RESIST-TB released its July 2022 newsletter with the latest research publications on drug-resistant TB.
New antibiotic resistance genes identified in TB (post)
A massive analysis of more than 10,000 different Mycobacterium tuberculosis bacteria isolates from 23 countries has revealed new genes associated with resistance to 13 first- and second-line new and repurposed antibiotics. The work, carried out by Comprehensive Resistance Prediction for Tuberculosis: an International Consortium (CRyPTIC), is described in two new papers publishing August 11th in the open-access journal PLOS Biology.
‘Patients are falling through the cracks’: drug costs hinder India’s response to TB (post)
The country has the world’s largest number of multi-drug-resistant cases – but doctors and activists warn patients are going undiagnosed and untreated.
PAN-TB collaboration to advance investigational TB drug regimens to Phase 2 clinical trials (post)
Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations.
RESIST-TB September 2022 newsletter (post)
RESIST-TB released its September 2022 newsletter with the latest research publications on drug-resistant TB.
Illumina and GenoScreen partner to expand access to genomic testing for multidrug-resistant TB (post)
SAN DIEGO, Oct. 18, 2022 -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, today announced a partnership to accelerate progress to end tuberculosis (TB) worldwide. The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB (MDR-TB). This alliance will enable global access to a package combining Illumina sequencing products and the GenoScreen Deeplex® Myc-TB assay, a targeted next-generation sequencing (NGS) based test for rapid and extensive detection of anti-TB drug resistance, to promptly inform treatment decision. This will help advance the World Health Organization's (WHO) strategy to end the global TB epidemic by 2035.
RESIST-TB October 2022 newsletter (post)
RESIST-TB released its October 2022 newsletter with the latest research publications on drug-resistant TB.
Shorter treatment effective for drug-resistant TB (post)
Two treatment regimens for multidrug-resistant TB, containing the first new drug to have been discovered for the disease in 40 years, are more effective than a previously recommended treatment, according to results from a global trial led by UCL researchers.
Linezolid at lower doses may be more tolerable for multidrug-resistant TB (post)
Improved outcomes and increased treatment tolerability to linezolid were observed in patients with multidrug-resistant tuberculosis who switched to a lower dose.
Page 77 of 117 · Total posts: 0
←First 76 77 78 Last→